Integrated data analysis results indicated that ustekinumab-treated patients ( regardless of dose ) demonstrated significantly less radiographic progression at wk @ than did placebo recipients ( wk @-@ total vdH-S score mean changes : @-combined / individual ustekinumab dose groups , @-placebo ; all p < @ ) .